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Introduction

Pathophysiological Processes

What is the topic?
Pheochromocytoma and Paraganglioma
(PPGL)

Underlying
Pathophysiology
•

•

Retrieved from
http://urologyspecialist.com.au/what-isapheochromocytoma/1pheochromocytom
a/
•

Why choose PPGL?
•
•
•

•
•

•

•
•

•

Possible malignant catecholamine
secreting tumor
Incidence in general population:
0.005-0.1%
Incidence in adult hypertensive
population: 0.1-0.2% (Farrugia et
al., 2017)
Direct relation to my past nursing
practice in a surgical-oncology
progressive care unit
Close monitoring of vital signs and
assessments preoperatively and
postoperatively
Potential to cause fatal
complications if left untreated
(Hekimian et al., 2016)
No official guidelines for treatment
(Jimenez, Tatsui, Jessop, Thosani, &
Jimenez, 2017)
Field of genetics and pheo’s
undergoing significant changes in
understanding (Farrugia et al.,
2017; Kantorovich & Pacak, 2018)
Pheochromocytomas and
paragangliomas are the highest
hereditary-driven endocrine
condition (Kantorovich & Pacak,
2018)
•
40% related to
mutations in well
established 15 drivergenes. Numbers are
expected to grow

•

•

•

Exact cause is unknown (Hines &
Marschall, 2018)
•
90% are an isolated
finding
•
10% inherited as
autosomal dominant
Chromaffin cell tumors originating
from neural crest cells from the
adrenal medulla and extra-adrenal
sites (Manimaran, Khan, Bharathi,
Thulasi, & Anuradha, 2016)
•
80-85% from
adrenal medulla
•
15-20% extraadrenal: organ of
Zuckerkandl, neck,
thorax, bladder, and
prostate
Most pheochromocytomas secrete
norepinephrine and epinephrine at
a 85:15 ratio (Nagelhout & Elisha,
2018, Hines & Marschall, 2018)
•
15% secrete
epinephrine
predominantly
•
Can also secrete
dopamine, though
less common
Neural stimulation does not cause
hormone release due to lack of
innervation
“Rule of ten”: Both adrenal glands
involved in 10% of adults with
tumor, 10-15% extraadrenal, and
at least 10% are malignant
Malignant spread typically through
venous and lymphatic channels to
liver (Nagelhout & Elisha, 2018)

•

•

•

•

•

Genetic Significance
in Pathophysiology

Anatomic classifications fall short of
providing sufficient insight into
pathogenesis, clinical presentation, and
prognostic value with respect to
malignant potential
Functional, pathogenesis-based
classification may offer better
understanding of actual tumorigenesis,
expected biochemical profiles, tumor
location, and malignant potential
Functional classification of current
established susceptibility genes:
• Pseudohypoxia group
• Kinase signaling group
• Wnt signaling group
• Disease-modifying gene
group
Pathogenesis-based knowledge help
design new therapeutic approaches
that target specific gene pathways
• Example: Hypoxiainducible factor 2⍺
antagonist (HIF-2⍺)
which promote HIF
hydroxylation and
degradation of
substances that promote
tumorigenesis at a
specific pathogenetic
point
Additional clinical presentations and
genetic mutations will create
opportunities to further understand
the pathophysiology of
pheochromocytoma and
paraganglioma (Kantorovich & Pacak,
2019)

Signs & Symptoms
•

•

•

Main signs and symptoms
(catecholamine excess)
•
Hypertension
•
Palpitations
•
Headache
•
Perspiration
•
Pallor
•
Tremors
•
Anxiety
Less common signs and symptoms
(Farrugia et al., 2017; Hekimian et
al., 2016)
•
Fatigue
•
Abdominal pain
•
Nausea
•
Vomiting
•
Myalgia
•
Weight loss
•
Constipation
•
Flushing
•
Fever
Potential manifestations if
untreated (Hekimian et al., 2016)
•
Myocardial infarction
•
Cardiogenic shock
•
Takotsubo-like
cardiomyopathy
•
Hypertensive crisis
•
Pulmonary edema
•
Cerebral vascular
accident
•
Dysrhythmias

•

•

•

•

•

Implications for
Nursing Care

Close monitoring of BP, HR, pulse
oximetry
•
Signs can occur once a
month or multiple times
per day ranging
minutes to hours
24-hour urine collection of
metanephrines and catecholamines or
measurement of plasma free
metanephrines
Telemetry monitoring for
abnormalities:
•
Elevation or depression
of ST segment
•
Flattening or inversion
of T wave
•
Prolongation of QT
interval
•
High or peaked P waves
Emphasis on BP mgmt. (Hines &
Marschall, 2018)
•
Alpha blockade before
beta blockade
•
Blocking vasodilatory
β2-receptors results in
unopposed ⍺-agonism
à vasoconstriction and
hypertensive crisis
Preoperative goals (Hines &
Marschall, 2018; Tsegay, Anyango,
Van Sell, & Miller-Anderson, 2008)
•
Euvolemia
•
Normotensive: Below
160/90 mmHg for at
least 24 hours before
surgery

Removal
Surgical resection is the primary treatment strategy
High risk for morbidity and mortality in the
perioperative period (Bai et al., 2018)
•
Can be as high as 50%
•
Improvements in preoperative medical
preparation, anesthesia, and surgical
techniques have reduced risk to 0-2.9%
Cardiovascular related complications occurred in 24%
of patients who underwent removal in a study by Bai et
al. 2018, which compared similarly to previous
research.
•
Postoperative hypotension
•
Arrhythmia
•
Myocardial infarction
Peripheral vasoconstriction induced by catecholamines
preoperatively leads to possible use of vasoactive
agents (norepinephrine) and volume expansion with
crystalloid or colloid products
Prolonged exposure of catecholamines to the
myocardium and coronary arteries could presumably
lead to collagen deposition and fibrosis in the
myocardium
Acute left cardiac dysfunction due to chronically
elevated epinephrine was a root cause of hypotension
and circulatory failure after pheochromocytoma
removal
Possible independent risk factors for severe morbidity
(Bai et al., 2018)
•
Female sex
•
Coronary heart disease
•
BMI of 22 ± 2.9
•
Intraoperative hemodynamic instability
•
Longer duration of surgery: 171.1 ± 73
minutes
•
4 of the 262 patients that died in this
study all had coronary heart disease and
died of circulatory collapse

•
•

•

•

•

•

•

Conclusion
•
•
•
•

•

•
Retrieved from https://www.medicalnewstoday.com/articles/318203.php
Retrieved from https://artsugar.co/products/pheocrhomocytoma

Pheochromocytoma and paraganglioma are rare
neuroendocrine tumors associated with
catecholamine production
Surgical resection is the primary treatment
Genetic research has provided additional
information regarding pathogenesis and targeted
treatment
The classic triad of diaphoresis, palpitations, and
headache has a reported sensitivity of 89% and
specificity of 67% for pheochromocytoma
specifically. In the presence of hypertension, it
raises to 91% and 94%, respectively
Rarity and variability of these tumors make them
difficult to manage and many are discovered
incidentally during radiologic examinations or at
autopsy
The key to diagnosing is to first think of it! (Bai et
al., 2018; Farrugia et al., 2017)
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